Global Blood Therapeutics, Inc. is focused on building a pipeline of innovative, oral medicines to revolutionize the treatment of chronic, genetic blood-based diseases for which there are currently no cures available and only extremely limited therapeutic options.

Global Blood Therapeutics' lead program focuses on Sickle Cell Disease (SCD), one of the earliest rare genetic diseases to be defined on a molecular basis.